2seventy bio (TSVT) has shared an announcement.
2seventy bio, Inc. has entered into a lucrative deal with Novo Nordisk A/S, selling its gene therapy research program for an upfront $38 million in cash and the potential for an additional $2 million. This program focuses on the treatment and prevention of hemophilia. Novo Nordisk will take on certain liabilities and both companies have agreed to indemnify each other against certain losses. This strategic move will likely stir interest among stock market enthusiasts as 2seventy bio reshapes its portfolio and Novo Nordisk expands its healthcare offerings.
See more insights into TSVT stock on TipRanks’ Stock Analysis page.
